On April 25, 2022 Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumors, reported that Dr. Cheng Liu, President and CEO, to participate in person at the PEGS Boston Conference and Expo at Hynes Convention Center on May 2-6, 2022 (Press release, Eureka Therapeutics, APR 25, 2022, View Source [SID1234612926]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Liu will be participating in two engagements. He will be hosting a roundtable discussion on the challenges and opportunities of targeting intracellular antigens and presenting Eureka’s approach of using TCR-mimic antibodies to target intracellular antigens, both in the Oncology Stream – Antibodies for Cancer Therapy Track.